Skip to main content
main-content

15.09.2015 | Onkologie | Onlineartikel

Novel approaches in small-cell lung cancer

Small-cell lung cancer (SCLC) accounts for approximately 15 % of all lung cancers, and it is associated with poor outcomes [1]. 70 % of these patients present with extensive disease. Their treatment remains a significant challenge for oncologists. The median survival in the extensive disease stage is 7 months to 9 months, and only 2 % of patients survive for 5 years [2]. So far, many attempts to improve upon these results in the first-line setting have failed.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten